SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-054082
Filing Date
2024-04-29
Accepted
2024-04-29 16:30:30
Documents
6
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm243018-1_def14a.htm DEF 14A 424499
2 GRAPHIC lg_nuvectispharma-4clr.jpg GRAPHIC 10226
3 GRAPHIC sg_ronbentsur-bw.jpg GRAPHIC 6671
4 GRAPHIC sg_michaelcarson-bw.jpg GRAPHIC 17169
5 GRAPHIC px_24nuvectisproxy1pg1-bw.jpg GRAPHIC 213598
6 GRAPHIC px_24nuvectisproxy1pg2-bw.jpg GRAPHIC 170906
  Complete submission text file 0001104659-24-054082.txt   945322
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

IRS No.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41264 | Film No.: 24891457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)